Berenberg Bank set a €150.00 ($174.42) target price on MorphoSys (ETR:MOR) in a research note issued to investors on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also weighed in on MOR. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on shares of MorphoSys and gave the company a buy rating in a report on Wednesday, August 7th. Royal Bank of Canada set a €130.00 ($151.16) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Friday, August 9th. Independent Research set a €116.00 ($134.88) target price on shares of MorphoSys and gave the stock a neutral rating in a research report on Tuesday, August 13th. HSBC set a €81.00 ($94.19) target price on shares of MorphoSys and gave the stock a sell rating in a research report on Friday, August 16th. Finally, Deutsche Bank set a €133.00 ($154.65) price target on shares of MorphoSys and gave the company a buy rating in a research note on Thursday, August 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. MorphoSys has a consensus rating of Hold and a consensus price target of €119.67 ($139.15).

ETR MOR opened at €106.50 ($123.84) on Monday. The stock has a market cap of $3.36 billion and a PE ratio of -80.62. MorphoSys has a 12 month low of €76.45 ($88.90) and a 12 month high of €114.70 ($133.37). The company’s 50-day moving average price is €107.51 and its 200-day moving average price is €93.29. The company has a current ratio of 7.62, a quick ratio of 7.40 and a debt-to-equity ratio of 8.61.

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Featured Article: Momentum Indicator: Relative Strength Index

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.